VCP and acute myeloid leukemia: Analysis of 483 pediatric AML patients from a children’s oncology group trial showed that low valosin-containing protein (VCP) expression was significantly linked to better five-year survival rates—81% in low VCP patients versus 63% in those with higher levels.